Lenvatinib Long-Term Responses in Refractory Thyroid Cancer: Our Mono-Institutional Real-Life Experience with the Multidisciplinary Approach and Review of Literature-Reference-Cited by-同舟云学术

Lenvatinib Long-Term Responses in Refractory Thyroid Cancer: Our Mono-Institutional Real-Life Experience with the Multidisciplinary Approach and Review of Literature

Published:2019 Issue:4 Volume:97 Page:206-210
ISSN:0030-2414
Container-title:Oncology
language:en
Short-container-title:Oncology

Author:

Denaro Nerina,Latina Adele,Cesario Flora,Bramardi Fabio,Corrado Lauro,Borretta Giorgio,Merlano Marco Carlo

Publisher

S. Karger AG

Subject

Cancer Research,Oncology,General Medicine

Reference5 articles.

1. Matsui J, Yamamoto Y, Funahashi Y, Tsuruoka A, Watanabe T, Wakabayashi T, et al. E7080, a novel inhibitor that targets multiple kinases, has potent antitumor activities against stem cell factor producing human small cell lung cancer H146, based on angiogenesis inhibition. Int J Cancer. 2008 Feb;122(3):664–71.

2. Schlumberger M, Tahara M, Wirth LJ. Lenvatinib in radioiodine-refractory thyroid cancer. N Engl J Med. 2015 May;372(19):1868.

3. Brose MS, Worden FP, Newbold KL, Guo M, Hurria A. Effect of Age on the Efficacy and Safety of Lenvatinib in Radioiodine-Refractory Differentiated Thyroid Cancer in the Phase III SELECT Trial. J Clin Oncol. 2017 Aug;35(23):2692–9.

4. Matrone A, Valerio L, Pieruzzi L, Giani C, Cappagli V, Lorusso L, et al. Protein kinase inhibitors for the treatment of advanced and progressive radiorefractory thyroid tumors: from the clinical trials to the real life. Best Pract Res Clin Endocrinol Metab. 2017 Jun;31(3):319–34.

5. Suyama K, Fujiwara S, Takeshita T, Sueta A, Inao T, Yamamoto-Ibusuki M, et al. Clinical features of lenvatinib treatment in elderly patients with advanced thyroid cancer. Mol Clin Oncol. 2017 Jul;7(1):24–6.

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Management of hypertension during lenvatinib for advanced thyroid cancer: a suggested diagnostic and therapeutic algorithm;European Thyroid Journal;2023-04-25

2. Daily Management of Patients on Multikinase Inhibitors’ Treatment;Frontiers in Oncology;2022-07-04

3. Lenvatinib: an investigational agent for the treatment of differentiated thyroid cancer;Expert Opinion on Investigational Drugs;2021-09-02

4. Personalized treatment for differentiated thyroid cancer: current data and new perspectives;Minerva Endocrinology;2021-03

5. Multikinase inhibitors in thyroid cancer: timing of targeted therapy;Nature Reviews Endocrinology;2021-02-18